Biotech Values

[DewDiligence]

Addendum re Big Pharma’s diversification trend:

After listening to yesterday’s ABT CC for the Solvay acquisition, I see that this deal is squarely aligned with the Big Pharma diversification trend you cited two years ago. Why? Because 70% of Solvay’s drug sales come from selling “branded generics,” largely in emerging markets. Thus, the ABT-Solvay deal is consistent with the way such companies as GSK, SNY, NVS (and ABT itself) have been reconfiguring their companies.